PRAX

Praxis Precision Medicines, Inc. [PRAX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PRAX Stock Summary

Top PRAX Correlated Resources

PRAX


Top 10 Correlated ETFs

PRAX


Top 10 Correlated Stocks

PRAX


In the News

11:56 28 Mar 2024 PRAX

Praxis (PRAX) Surges on Positive Epilepsy Study Results

Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.

01:34 28 Mar 2024 PRAX

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Phase 2b study targeting this very same patient population to be initiated 2nd half of 2024.

01:01 28 Mar 2024 PRAX

What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?

Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.

10:56 28 Mar 2024 PRAX

Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

09:11 28 Mar 2024 PRAX

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.97 per share versus the Zacks Consensus Estimate of a loss of $3.15. This compares to loss of $13.04 per share a year ago.

11:18 28 Mar 2024 PRAX

Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Praxis Precision Medicines, Inc. (PRAX) could be a good stock pick from a technical perspective. PRAX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

04:00 28 Mar 2024 PRAX

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com.

11:19 28 Mar 2024 PRAX

Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

09:02 28 Mar 2024 PRAX

New Strong Buy Stocks for October 11th

PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.

07:00 28 Mar 2024 PRAX

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society's (MDS) International Congress of Parkinson's Disease and Movement Disorders®, taking place in Copenhagen, Denmark.

PRAX Financial details

Company Rating
Neutral
Market Cap
713.15M
Income
-122.64M
Revenue
2.45M
Book val./share
7.69
Cash/share
8.97
Dividend
-
Dividend %
-
Employees
82
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-38.99
Forward P/E
-6.4
PEG
62.12
P/S
174.33
P/B
61.42
P/C
6.79
P/FCF
-2.9
Quick Ratio
6.02
Current Ratio
6.15
Debt / Equity
0.04
LT Debt / Equity
0.02
-
-
EPS (TTM)
-4.33
EPS next Y
-9.53
EPS next Q
-1.98
EPS this Y
-99.6%
EPS next Y
120.13%
EPS next 5Y
-386.49%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
10.04%
EPS Q/Q
1550%
-
-
-
-
SMA20
21.74%
SMA50
43.59%
SMA100
250%
Inst Own
106.9%
Inst Trans
0.49%
ROA
-128%
ROE
-164%
ROC
-1.56%
Gross Margin
100%
Oper. Margin
-7247%
Profit Margin
-7073%
Payout
-
Shs Outstand
13.24M
Shs Float
12.58M
-
-
-
-
Target Price
-
52W Range
11.85-59.975
52W High
+3.3%
52W Low
+454.05%
RSI
62
Rel Volume
8.73
Avg Volume
166.23K
Volume
1.45M
Perf Week
9.06%
Perf Month
47.42%
Perf Quarter
165.56%
Perf Half Y
187.07%
-
-
-
-
Beta
2.86
-
-
Volatility
4.23%, 6.14%
Prev Close
2.95%
Price
60.945
Change
-1.99%

PRAX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.07-1.62-3.93-4.62-0.02
Operating cash flow per share
-1.95-1.38-2.93-4.01-0.02
Free cash flow per share
-1.95-1.37-2.96-4.02-0.02
Cash per share
2.617.756.52.180.01
Book value per share
2.347.515.911.650.01
Tangible book value per share
2.347.515.911.650.01
Share holders equity per share
2.347.515.911.650.01
Interest debt per share
0.080.020.20.090
Market cap
7.16B31.58B12.55B1.65B146.92B
Enterprise value
7.12B31.29B12.41B1.59B146.84B
P/E ratio
-201.7-510.89-75.18-7.72-1.19K
Price to sales ratio
000060.04K
POCF ratio
-214.33-600.18-100.72-8.89-1.32K
PFCF ratio
-213.67-600.22-99.88-8.87-1.32K
P/B Ratio
178.57109.8750.0221.622.11K
PTB ratio
178.57109.8750.0221.622.11K
EV to sales
000060.01K
Enterprise value over EBITDA
-200.22-504.89-74.17-7.39-1.17K
EV to operating cash flow
-213.03-594.55-99.64-8.58-1.32K
EV to free cash flow
-212.38-594.6-98.81-8.56-1.32K
Earnings yield
00-0.01-0.130
Free cash flow yield
00-0.01-0.110
Debt to equity
0.0400.030.060.04
Debt to assets
0.0300.030.040.03
Net debt to EBITDA
1.224.770.80.270.63
Current ratio
6.6719.237.643.125.39
Interest coverage
000513.090
Income quality
0.940.850.750.860.9
Dividend Yield
00000
Payout ratio
0-0.01000
Sales general and administrative to revenue
000017.19
Research and developement to revenue
000035.46
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
0000-0.02
Capex to depreciation
-2.780.08-5.77-1.06-0.12
Stock based compensation to revenue
000010.16
Graham number
10.4216.5222.8613.10.07
ROIC
-0.83-0.21-0.63-2.54-1.69
Return on tangible assets
-0.74-0.2-0.57-1.85-1.4
Graham Net
2.177.345.511.330.01
Working capital
38.68M286.61M249.79M75.32M69.13M
Tangible asset value
40.11M287.46M250.81M76.11M69.67M
Net current asset value
37.92M286.61M245.47M71.82M66.6M
Invested capital
0.0400.030.060.04
Average receivables
00000
Average payables
3.03M3.38M7.43M12.73M10.24M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
1.43K2K2.47K4.57K4.91K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.250.180.150.080.07
Inventory turnover
00000
ROE
-0.89-0.22-0.67-2.8-1.77
Capex per share
-0.010-0.02-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.010.0100.06
Net income per share
-0.86-0.69-0.49-0.18-2.97
Operating cash flow per share
-0.61-0.62-0.45-0.17-2.63
Free cash flow per share
-0.61-0.62-0.45-0.17-2.64
Cash per share
2.111.621.780.758.97
Book value per share
1.61.211.510.647.69
Tangible book value per share
1.61.211.510.647.69
Share holders equity per share
1.61.211.510.647.69
Interest debt per share
0.090.080.040.020.28
Market cap
1.7B644.67M1.2B3.48B201.87M
Enterprise value
1.64B567.09M1.08B3.38B123.07M
P/E ratio
-10.39-4.38-8.77-35.3-1.88
Price to sales ratio
0943.881.54K7.43K391.99
POCF ratio
-58.99-19.63-38.54-149.81-8.46
PFCF ratio
-58.99-19.63-38.54-149.81-8.44
P/B Ratio
22.331011.3940.092.9
PTB ratio
22.331011.3940.092.9
EV to sales
0830.291.39K7.22K238.97
Enterprise value over EBITDA
-39.61-14.89-31.04-132.45-4.44
EV to operating cash flow
-57-17.27-34.66-145.58-5.16
EV to free cash flow
-57-17.27-34.66-145.58-5.15
Earnings yield
-0.02-0.06-0.03-0.01-0.13
Free cash flow yield
-0.02-0.05-0.03-0.01-0.12
Debt to equity
0.060.070.030.030.04
Debt to assets
0.040.040.020.030.03
Net debt to EBITDA
1.382.043.483.852.85
Current ratio
3.123.085.316.155.39
Interest coverage
394.79359.35000
Income quality
0.70.880.910.940.89
Dividend Yield
00000
Payout ratio
-0.01-0.01-0.01-0.010
Sales general and administrative to revenue
019.4312.9718.6419.29
Research and developement to revenue
037.3432.836.8835.7
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
0000-0.1
Capex to depreciation
0000-0.45
Stock based compensation to revenue
011.127.3912.3111.12
Graham number
5.564.354.091.6222.65
ROIC
-0.49-0.52-0.31-0.28-0.37
Return on tangible assets
-0.36-0.37-0.26-0.23-0.31
Graham Net
1.290.981.380.66.96
Working capital
75.32M63.75M105.4M86.54M69.13M
Tangible asset value
76.11M64.47M105.63M86.76M69.67M
Net current asset value
71.82M60.49M101.96M83.36M66.6M
Invested capital
0.060.070.030.030.04
Average receivables
00000
Average payables
12.4M15.83M12.5M7.59M6.49M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
4.39K4.98K2.31K2.01K4.71K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.020.020.040.040.02
Inventory turnover
00000
ROE
-0.54-0.57-0.32-0.28-0.39
Capex per share
0000-0.01

PRAX Frequently Asked Questions

What is Praxis Precision Medicines, Inc. stock symbol ?

Praxis Precision Medicines, Inc. is a US stock , located in Boston of Ma and trading under the symbol PRAX

What is Praxis Precision Medicines, Inc. stock quote today ?

Praxis Precision Medicines, Inc. stock price is $60.945 today.

Is Praxis Precision Medicines, Inc. stock public?

Yes, Praxis Precision Medicines, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap